Swiss National Bank Igm Biosciences, Inc. Transaction History

Swiss National Bank

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$8.86 - $14.0 $58,475 - $92,400	6,600 Added 30.0%	28,600 $263,000
Q1 2023 May 10, 2023	SELL	$13.74 - $25.76 $34,350 - $64,400	-2,500 Reduced 10.2%	22,000 $302,000
Q4 2022 Feb 08, 2023	BUY	$15.45 - $26.02 $27,810 - $46,836	1,800 Added 7.93%	24,500 $416,000
Q3 2022 Nov 09, 2022	BUY	$15.42 - $27.01 $18,504 - $32,412	1,200 Added 5.58%	22,700 $516,000
Q2 2022 Aug 09, 2022	BUY	$13.27 - $25.5 $39,810 - $76,500	3,000 Added 16.22%	21,500 $388,000
Q1 2022 May 09, 2022	BUY	$13.42 - $29.73 $20,130 - $44,595	1,500 Added 8.82%	18,500 $495,000
Q3 2021 Nov 08, 2021	BUY	$65.76 - $90.65 $26,304 - $36,260	400 Added 2.41%	17,000 $1.12 Million
Q1 2021 May 07, 2021	BUY	$71.56 - $121.23 $14,312 - $24,246	200 Added 1.22%	16,600 $1.27 Million
Q4 2020 Feb 05, 2021	BUY	$47.41 - $115.03 $14,222 - $34,509	300 Added 1.86%	16,400 $1.45 Million
Q2 2020 Aug 05, 2020	BUY	$51.3 - $75.21 $825,930 - $1.21 Million	16,100 New	16,100 $1.18 Million

20.7M

68K

52.2K

Ticker IGMS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,969,000
Market Cap $189M
Description
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.